Clinical Trial

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Name: Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients — clinical trial record (NCT07473167)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: TC011

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.

Trial Details

NCT Number	NCT07473167
Lead Sponsor	TICAROS Co., Ltd.
Conditions	Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma (HGBL), Transformed Follicular Lymphoma (TFL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Enrollment	98 participants
Start Date	2023-08-03
Primary Completion	2028-02-11 (estimated)
Study Completion	2028-03-10 (estimated)
Updated on ClinicalTrials.gov	2026-03-16